GPN00884

GPN00884 is an investigational ophthalmic eye drop formulation being developed by Grand Pharma for delaying myopia progression in children. Public disclosures describe it as a global innovative ophthalmic drug with a new mechanism of action relative to low-concentration atropine, but the specific active ingredient and biological target have not been publicly disclosed. Grand Pharma has stated that, unlike atropine eye drops, GPN00884 is intended to avoid mydriasis and atropine-associated adverse effects such as photophobia and reduced accommodation, potentially allowing more flexible dosing and better compliance. The program originated from technology and intellectual property acquired from the Eye Hospital of Wenzhou Medical University and has advanced in China from Phase 1 into Phase 2 clinical testing for pediatric myopia progression.

Other names

GPN00884 eye dropsGPN-00884 eye dropsGPN 00884 eye drops